Unigen Lifesciences Oxavar (Anavar/Oxandrolone) 10mg x 50Oxandrolone is a mild, low androgen alpha alkylated anabolic steroid with very low toxicity. It promotes protein steroid psychosis and hallucinations symptoms and has a low incidence of adverse reactions. Oxandrolone is primarily used to promote strength, anavar unigen life sciences hardness and quality physique improvement. In the International Journal of Obesity; Oxavar 10 tablets contain 10 mg of the oral anabolic steroid Oxandrolone. Anabolic steroids are synthetic derivatives of testosterone, having actions similar to the endogenous male sex hormone testosterone. There is not a complete dissociation of the anabolic versus androgen action.
Unigen Lifesciences Oxavar (Anavar/Oxandrolone) 10mg x 50
Oxandrolone is a mild, low androgen alpha alkylated anabolic steroid with very low toxicity. It promotes protein anabolism and has a low incidence of adverse reactions. Oxandrolone is primarily used to promote strength, muscle hardness and quality physique improvement. In the International Journal of Obesity , ; Oxavar 10 tablets contain 10 mg of the oral anabolic steroid Oxandrolone. Anabolic steroids are synthetic derivatives of testosterone, having actions similar to the endogenous male sex hormone testosterone.
There is not a complete dissociation of the anabolic versus androgen action. Anabolic steroids may suppress gonadotrophic function of the pituitary and may also have a direct effect on the testes. During exogenous administration of anabolic steroids and androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone LH. With large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone FSH.
The actions of anabolic steroids are similar to male sex hormones. Anabolic steroids may cause growth disturbances and induce premature sexual development if administered to young children. Lipids levels generally return to normal upon discontinuation of treatment. In a single dose pharmacokinetic study of oxandrolone in geriatric subjects, the average elimination half-life was In a similar pharmacokinetic study in younger subjects, the average elimination half-life was No significant differences between geriatric and younger test subjects were found for time to peak absorption, peak plasma concentration, or AUC after a single dose.
The correlation between plasma level and therapeutic effect has not yet been established. Oxavar is indicated to compensate for protein catabolism consequent to corticosteroid therapy and for the reduction of pain associated with osteoporosis. Diagnosed or suspected female breast carcinoma with hypercalcemia as androgenic agents may increase osteolytic bone resorption.
Women who are pregnant or may become pregnant because of possible masculinization of the fetus. Peliosis Hepatis has been reported in patients receiving androgenic anabolic steroid therapy.
This condition may include blood-filled cyst formation in the liver and may present with or without hepatic dysfunction. Termination of the steroid therapy generally results in the disappearance of the lesions. Liver cell tumors have also been reported, most often benign and androgen-dependent, although malignant tumors have also been reported.
Termination of the drug, generally results in cessation of tumor progression or regression. Androgenic anabolic steroids have been associated with changes in serum lipids, generally with decreases in high-density lipoprotein HDL concentration and increases in low-density lipoprotein LDL concentration, a profile known to be associated with increased risk of atherosclerosis and associated risk of coronary artery disease.
Oxandrolone therapy may cause hypercalcemia by stimulating osteolysis in breast cancer patients. If hypercalcemia occurs, oxandrolone therapy should be discontinued. Edema may be increased in patients on concurrent adrenal cortical steroid or ACTH therapy. When oxandrolone is administered to patients undergoing warfarin treatment, the dosing of warfarin may need to be reduced significantly to maintain the desired INR level and reduce the risk of serious bleeding.
Women on oxandrolone therapy should be observed for signs of virilization which may include the deepening of the voice, hirsutism, or, clitoromegaly. Therapy should be discontinued upon signs of virilism to reduce the risk of irreversible virilization. Some virilizing effects may be irreversible after cessation of therapy even with concurrent administration of estrogens. Menstrual irregularities may also occur.
Patients should be instructed to report any use of warfarin and any irregular bleeding. Frequent or persistent penile erections and increases in the appearance of acne vulgaris. Hoarseness of the voice, acne, changes in menstrual periods, or more facial hair.
Periodic liver function tests should be conducted given the association of alpha-alkylated androgens with hepatotoxicity. If cholestatic hepatitis with jaundice appears or if liver function tests LFT become abnormal, oxandrolone the.
Liver function tests should be obtained periodically during therapy. Examination of bone age by x-ray should be conducted during treatment of children to determine bone maturation rate and effect on epiphyseal centers.
Women with breast carcinoma should have frequent assays of serum and urine calcium throughout the course of treatment. Androgenic anabolic steroids have been associated with increases in low-density lipoproteins and reduction in high-density lipoproteins in serum.
Caution is indicated when administering such medications to patients with cardiovascular disease or at risk for cardiovascular disease. Periodic serum lipid assays are recommended during treatment. Serum assays for hematocrit and hemoglobin are recommended to screen for polycythemia in patients receiving large doses of androgenic anabolic steroids.
Anabolic steroids have been shown to reduce concentration of thyroxine-binding globulin and consequently decreasing the total serum T4 and increasing uptake of both T3 and T4. Serum concentration of free unbound thyroid hormones will not change. Anabolic steroids may decrease PBI and iodine uptake. Oxandrolone may inhibit the metabolism of oral hypoglycemic agents which may require adjustment of dosage. Oxandrolone may exacerbate edema in patients on concurrent adrenal-cortical steroids or ACTH therapy.
Patients on anticoagulants such as warfarin should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants which may require a concomitant reduction in anticoagulant dosage to achieve a desirable prothrombin time PT. Anticoagulant patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy. Such patients should be monitored for occult bleeding.
Pregnant women should not receive oxandrolone therapy due to possible masculinization of the fetus. In animal studies, oxandrolone in extremely high doses has demonstrated embryotoxicity, fetotoxicity, infertility, and masculinization of female offspring. It is not known whether anabolics are excreted in milk, but due to the harm the drug may give infants, a decision should be made by the nursing mother whether to continue the drug or not.
Use in children should be closely monitored by x-ray due to the potential for accelerating epiphyseal maturation and potentially compromising adult height. Great caution should be observed during therapy. Peliosis hepatis, cholestatic jaundice, and very rarely hepatic necrosis. Retention of electrolytes including sodium, potassium, chlorine, phosphates, and calcium.
Increased serum creatinine phosphokinase CPK , reduced glucose tolerance, increased creatinine clearance, and inhibition of gonadotrophin secretion. Increased frequency of erections and enlargement of the phallus, as well as more persistent erections. Inhibition of testicular function, chronic priapism, oligospermia, impotence, epididymitis, and bladder irritability.
No antidotes are known. In event of overdose, gastric lavage may be used. Daily dosage of 5 mg to 20 mg in 2 to 4 divided doses may be required to achieve the desired response. Therapy may be repeated intermittently as indicated. E ach uncoated tablet contains: Oxandrolone USP 10mg Oxandrolone is a mild, low androgen alpha alkylated anabolic steroid with very low toxicity.
Oxandrolone is also prescribed for the treatment of osteoporosis. Diagnosed or suspected male breast carcinoma or carcinoma of the prostate. Nephrosis and the nephrotic phase of nephritis. Nausea, vomiting, changes in skin color, or ankle swelling. If cholestatic hepatitis with jaundice appears or if liver function tests LFT become abnormal, oxandrolone the rapy should be discontinued pending determination of the etiology. Adrenal steroids or AC TH: Pregnancy Category X Pregnant women should not receive oxandrolone therapy due to possible masculinization of the fetus.
Changes in libido, habituation, excitation, insomnia, and depression. Bleeding on concomitant anticoagulant therapy. Deepening of the voice in females. Hirsutism and male pattern baldness androgenetic alopecia in females. Acne Vulgaris, particularly in females and pre-pubertal males. Premature closure of epiphyses in children.
Virilization including clitoral enlargement and menstrual irregularities. No symptoms or signs associated with oxandrolone overdose have been reported. Geriatric dosing of 5 mg twice per day is recommended. The duration of therapy will vary with the patient and the extent of adverse side effects. Unigen Life Sciences Ltd.